Progressive Familial Intrahepatic Cholestasis (PFIC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033


 Progressive familial intrahepatic cholestasis (PFIC) is an inherited liver condition that hinders bile drainage despite open large bile ducts, leading to cholestasis. It typically presents in early childhood with pruritus, dark urine, pale stool, decreased appetite, and fatigue. PFIC is categorized into three subtypes: PFIC type 1, PFIC type 2, and PFIC type 3, each linked to mutations in the ATP8B1, ABCB11, and ABCB4 genes, respectively. However, some PFIC cases lack these specific gene mutations. Signs and symptoms encompass severe itching (pruritus), inadequate weight gain due to impaired fat digestion and absorption, jaundice (skin yellowing), bleeding due to vitamin K deficiency, and poor bone growth from vitamin D deficiency. Various treatment options, both medical and surgical, are available. The primary medical treatment for all PFIC variants is ursodeoxycholic acid (UDCA). Nevertheless, most PFIC patients develop end-stage liver disease with significant fibrosis in adulthood. Due to the condition's progressive nature, those who do not undergo liver transplantation face a high risk of morbidity and mortality. Complications frequently stem from portal hypertension, including esophageal and gastric varices, leading to severe bleeding, ascites, hemorrhoids, and hepatic encephalopathy. Moreover, end-stage liver disease elevates the risk of hepatocellular carcinoma, particularly in cirrhotic patients. PFIC2 individuals may have an independent risk of malignancy regardless of cirrhosis.

·       The estimated incidence of PFIC in the United States ranges from 1 in 50,000 to 1 in 100,000 births.

 

Thelansis’s “Progressive Familial Intrahepatic Cholestasis (PFIC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive Familial Intrahepatic Cholestasis (PFIC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Progressive Familial Intrahepatic Cholestasis (PFIC) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Progressive Familial Intrahepatic Cholestasis (PFIC) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Progressive Familial Intrahepatic Cholestasis (PFIC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Progressive Familial Intrahepatic Cholestasis (PFIC), Progressive Familial Intrahepatic Cholestasis (PFIC) market outlook, Progressive Familial Intrahepatic Cholestasis (PFIC) competitive landscape, Progressive Familial Intrahepatic Cholestasis (PFIC) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments

Post a Comment

Popular posts from this blog

Motor Neurone Disease (MND) – Market Access and Reimbursement Insights Report – 2025

Motor Neurone Disease (MND) Market Access and Reimbursement Insights Thelansis’s “Motor Neurone Disease (MND) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Motor Neurone Disease (MND) Overview Motor neurone disease is a progressive neurological condition in which the nerve cells that control voluntary muscle movement gradually deteriorate. As these neurons are lost, muscles weaken and shrink, leading to increasing difficulty with walking, speaking, swallowing, and eventually breathing. The disease usually begins subtly but advances relentlessly, with most patients facing a shortened life expectancy of only a few ye...
Read more

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more